GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (NSE:GLENMARK) » Definitions » Shiller PE Ratio

Glenmark Pharmaceuticals (NSE:GLENMARK) Shiller PE Ratio : 33.48 (As of May. 06, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Shiller PE Ratio?

As of today (2024-05-06), Glenmark Pharmaceuticals's current share price is ₹1053.30. Glenmark Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was ₹31.46. Glenmark Pharmaceuticals's Shiller PE Ratio for today is 33.48.

The historical rank and industry rank for Glenmark Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

NSE:GLENMARK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 4.48   Med: 12.58   Max: 34.33
Current: 33.51

During the past years, Glenmark Pharmaceuticals's highest Shiller PE Ratio was 34.33. The lowest was 4.48. And the median was 12.58.

NSE:GLENMARK's Shiller PE Ratio is ranked worse than
66.98% of 533 companies
in the Drug Manufacturers industry
Industry Median: 25.13 vs NSE:GLENMARK: 33.51

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Glenmark Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was ₹-12.450. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is ₹31.46 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Glenmark Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Glenmark Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals Shiller PE Ratio Chart

Glenmark Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 4.72 12.94 12.63 13.64

Glenmark Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.66 13.64 19.53 25.41 27.15

Competitive Comparison of Glenmark Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Glenmark Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glenmark Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Glenmark Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Glenmark Pharmaceuticals's Shiller PE Ratio falls into.



Glenmark Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Glenmark Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=1053.30/31.46
=33.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glenmark Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Glenmark Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-12.45/153.2548*153.2548
=-12.450

Current CPI (Dec. 2023) = 153.2548.

Glenmark Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 1.590 91.425 2.665
201406 6.810 94.103 11.091
201409 6.090 96.780 9.644
201412 4.230 96.780 6.698
201503 0.390 97.163 0.615
201506 6.910 99.841 10.607
201509 7.660 101.753 11.537
201512 6.950 102.901 10.351
201603 5.070 102.518 7.579
201606 7.730 105.961 11.180
201609 7.770 105.961 11.238
201612 16.290 105.196 23.732
201703 0.750 105.196 1.093
201706 11.810 107.109 16.898
201709 7.240 109.021 10.177
201712 3.310 109.404 4.637
201803 5.350 109.786 7.468
201806 8.260 111.317 11.372
201809 14.670 115.142 19.526
201812 4.120 115.142 5.484
201903 5.730 118.202 7.429
201906 3.870 120.880 4.906
201909 9.060 123.175 11.272
201912 6.760 126.235 8.207
202003 7.810 124.705 9.598
202006 9.000 127.000 10.861
202009 8.290 130.118 9.764
202012 8.800 130.889 10.304
202103 8.290 131.771 9.642
202106 10.860 134.084 12.413
202109 9.130 135.847 10.300
202112 7.860 138.161 8.719
202203 5.510 138.822 6.083
202206 6.820 142.347 7.343
202209 9.230 144.661 9.778
202212 9.660 145.763 10.157
202303 -15.180 146.865 -15.840
202306 5.310 150.280 5.415
202309 -2.900 151.492 -2.934
202312 -12.450 153.255 -12.450

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Glenmark Pharmaceuticals  (NSE:GLENMARK) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Glenmark Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Glenmark Pharmaceuticals (NSE:GLENMARK) Business Description

Traded in Other Exchanges
Address
Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (NSE:GLENMARK) Headlines

No Headlines